Real-world Comparative Study of the Efficacy of Janus Kinase Inhibitors in Patients with Rheumatoid Arthritis: The ANSWER Cohort Study
Rheumatology 2023 doi 10.1093/rheumatology/kead543
This multicentre, retrospective study by Hayashi, et al. found no significant differences in efficacy and safety between tofacitinib, baricitinib, peficitinib and upadacitinib in patients with RA. Predictive factors for resistance to LDA achievement included baseline CRP and CDAI for tofacitinib and baseline glucocorticoid dose, baseline CDAI and number of previous b/tsDMARDs for baricitinib.
Patients (N=662) were selected from the ANSWER cohort database and treated with tofacitinib, baricitinib, peficitinib or upadacitinib. CDAI, CRP, and modified Health Assessment Questionnaire (mHAQ) after drug initiation were compared among the four groups. Predictive factors for tofacitinib and baricitinib efficacy was also analysed.
Keywords:
